Skip to Content

'
Robert F. Gagel, M.D.

Present Title & Affiliation

Primary Appointment

Head, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor, Department of Molecular & Cellular Biology, Baylor College of Medicine, Houston, TX

Bio Statement

I am Professor and Division Head of Internal Medicine, and also a Professor of Medicine and Cell Biology at Baylor College of Medicine.  My primary clinical interests have been in treatment of patients with hereditary and sporadic forms of medullary thyroid carcinoma.  My involvement with this disorder has spanned several decades from the initial development of calcitonin as a biomarker, through the identification and use of RET germline mutations in prophylactic surgery, to the recent establishment of vandetanib as the first FDA approved drug for the treatment of disseminated tumor.  My research group is currently examining molecular abnormalities of medullary thyroid carcinoma with a particular interest in cell cycle regulation and regulation of receptor tyrosine kinases .  I also have a focused interest in the areas of metabolic bone disease, including osteoporosis and hypercalcemia, and the biology of calcitonin and calcitonin gene-related peptide.  I serve as the Co-Director of the Rolanette and Berdon Lawrence Bone Disease Program of Texas at M.D. Anderson.  My leadership in medicine and large programs will be an essential component of this application.

Education & Training

Degree-Granting Education

1971 Ohio State University, Columbus, OH, BA, Arts-Medicine Program-resulting in both degrees being granted in 1971
1971 Ohio State University, Columbus, OH, MD, Medicine

Postgraduate Training

1973-1975 Fellow in Endocrinology, Tufts-New England Medical Center, Boston, MA, Seymour Reichlin, M.D., Ph.D.
1972-1973 Resident in Medicine, Tufts-New England Medical Center, Boston, MA, William Schwartz, M.D.
1971-1972 Intern in Medicine, Tufts-New England Medical Center, Boston, MA, William Schwartz, M.D.

Board Certifications

10/1977 Endocrinology and Metabolism
6/1975 Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Co-Director, Rolanette and Berdon Lawrence Bone Disease Program of Texas, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007-2012

Other Appointments/Responsibilities

Member, External Advisory Board, University of Cincinnati Cancer Center, Cincinnati, OH, 2004-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Wells SA, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767-72, 2/2010. e-Pub 1/2010. PMCID: PMC2834392.
2. Becklund BR, James BJ, Gagel RF, DeLuca HF. The calcitonin/calcitonin gene related peptide-alpha gene is not required for 1alpha, 25-dihydroxyvitamin D(3)-mediated suppression of experimental autoimmune encephalomyelitis. Arch Biochem Biophys 488(2):105-8, 8/15/2009. e-Pub 6/27/2009. PMID: 19563774.
3. Habra MA, Jimenez C, Huang SC, Cote GJ, Murphy WA, Gagel RF, Hoff AO. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr Pract 14(9):1108-14, 12/2008. PMID: 19158050.
4. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB, Perrier ND. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30(5):643-53, 5/2006. PMID: 16680581.
5. Yip L, Lee JE, Shapiro SE, Waguespack SG, Sherman SI, Hoff AO, Gagel RF, Arens JF, Evans DB. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525-34; discussion 534-5, 4/2004. PMID: 15051000.
6. Wohllk N, Becker P, Youlton R, Cote GJ, Gagel RF. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Rev Med Chil 129(7):713-8, 7/2001. PMID: 11552438.
7. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg 25(7):914-26, 7/2001. PMID: 11572033.
8. Kikumori T, Cote GJ, Gagel RF. Promiscuity of pre-mRNA spliceosome-mediated trans splicing: a problem for gene therapy? Hum Gene Ther 12(11):1429-41, 7/2001. PMID: 11485634.

Invited Articles

1. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, Shane E. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-91, 11/2007.
2. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Shah JP, Sisson JC, Tuttle RM, Urist MM, Urist MM. Thyroid carcinoma. J Natl Compr Canc Netw 5, No. 6(6):568-621, 7/2007. PMID: 17623612.
3. Jiménez C, Hu MI, Gagel RF. Management of Medullary Thyroid Carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. PMID: 18502338.
4. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 7(Supplement 3):S1-S32, 6/2009. PMID: 19555589.

Editorials

1. Cote GJ, Gagel RF. Lessons learned from the management of a rare genetic cancer. N Engl J Med 349:1566-8, 10/2003. PMID: 14561800.
Other Articles
1. Hu MI, Lu H, Gagel RF. Cancer therapies and bone health. Curr Rheumatol Rep 12(3):177-85, 6/2010. PMID: 20437119.
2. Ye L, Santarpia L, Gagel RF. Targeted Therapy for Endocrine Cancer: The Medullary Thyroid Carcinoma Paradigm. Endocr Pract 15(6):1-24, Sep-Oct, 9/2009. e-Pub 6/2009. PMID: 19546050.

Book Chapters

1. Hoff AO, Sherman SI, Gagel RF. Radioiodine treatment in differentiated thyroid malignancy. In: Endocrine Surgery of the Head and Neck. Ed(s) Pellitteri PK, McCaffrey TV. Delmar-Thomson Learning, Inc: Clifton Park, New York, pgs. 201-208, 2003.
2. Gagel RF, Cote GJ. Summary of gene disorders of serum mineral metabolism or skeleton formation. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. Ed(s) Favus MJ. Lippincott Williams & Wilkins: Philadelphia, pgs. 551-556, 2003.
3. Gagel RF, Shefelbine S, Hayashi H, Cote G. Multiple endocrine neoplasia type 2. In: Principles of Molecular Medicine. Ed(s) Runge MS, Patterson C. Humana Press: New Jersey, pgs. 393-399, 2006.
4. Gagel RF. Introduction to the Care of the Cancer Patient. In: Medical Care Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc: Shelton, CT, 1-2, 2009.
5. Hwang JP, Cooper SE, Gagel RF. Mechanisms of complications of malignancy. In: Medical Care of Cancer Patients, 1st ed. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc. Shelton, CT, 3-9, 2009.
6. Hu MI, Yeung SJ, Gagel RF. Endocrine paraneoplastic syndromes. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc. Shelton, CT, 194-204, 2009.
7. Yeung SJ, Gagel RF. Endocrine neoplastic syndromes. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc. Shelton, CT, 205-208, 2009.
8. Yeung SJ, Gagel RF. Pituitary and adrenal complications in cancer patients. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker, Inc: Shelton, CT, 237-241, 2009.
9. Yeung SJ, Escalante C, Gagel RF. Survivorship - A Reversal of Fortune. In: Medical Care of Cancer Patients, 1st. Ed(s) Yeung SJ, Escalante C, Gagel RF. B.C. Decker: Shelton, CT, 753-4, 2009.
10. Gagel RF, Marx SJ. Multiple endocrine neoplasia. In: Williams Textbook of Endocrinology. Chapter 40, 11th ed. Ed(s) Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Saunders: Philadelphia, 1705-46, 2008.
11. Gagel RF. Endocrine manifestations of tumors: "Ectopic" hormone production. In: Cecil Textbook of Medicine, Chapter 148; 23rd ed. Ed(s) Goldman, Ausiello. Saunders Elsevier: Philadelphia, pgs. 1349-53, 2008.
12. Defton LJ, Gagel RF. Medullary Thyroid Carcinoma and Calcitonin. In: Cecil Textbook of Medicine, Chapter 267; 23rd ed. Ed(s) Goldman L, Ausiello D. Saunders Elsevier: Philadelphia, pgs. 1906-10, 2008.
13. Gagel RF, Cote G. Molecular Diagnosis of Bone and Mineral Disorders. In: ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th. Ed(s) Rosen CJ, Compston JE, Lian JB. ASBMR: Washington, D.C., 193-6, 2008.
14. Hu MI, Gagel RF. Calcitonin Gene Family of Peptides. In: Principles of Bone Biology. 2, 3rd. Ed(s) Bilezikian JP, Raisz LG, Martin TJ. Academic Press Inc. San Diego, CA, 813-36, 2008.
15. Jimenez C, Gagel RF. Multiple endocrine neoplasias and autoimmune endocrinopathies. In: Harrison's Endocrinology, 2nd. Ed(s) Jameson JL. The McGraw-Hill Companies, Inc: New York, 367-378, 2010.

Books (edited and written)

1. Gagel RF. Ed(s) Yeung SJ, Escalante C, Gagel RF. Medical Care of Cancer Patients., 1st. B.C. Decker Inc. Shelton, CT, 2009.

Letters to the Editor

1. Evans DB, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. ASBMR JOMS, 2008.

Grant & Contract Support

Title: Advances in Bone Formation and Bone Metastasis (Health Care and Other Facilities)
Funding Source: Department of Health & Human Services Health Resources and Services Administration
Role: Principal Investigator
Duration: 9/1/2009 - 9/30/2014
 
Title: Advances in Bone Formation and Bone Metastasis (Health Care and Other Facilities)
Funding Source: Department of Health and Human Services Health Resources and Services Administration, HRSA
Role: Principal Investigator
Duration: 6/1/2008 - 9/30/2013
 
Title: UT M.D. Anderson Cancer Center CCOP Research Base
Funding Source: MDA Community Clinical Oncology Program (CCOP)
Role: Program Leader
Principal Investigator: Michael Fisch
Duration: 6/1/2007 - 6/1/2012
 
Title: Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Naifa Busaidy, MD
Duration: 1/1/2006 - 9/30/2011
 
Title: Paul Calabresi Clinical Oncology Award
Funding Source: NCI
Role: Advisory Committee Member/Mentor
Principal Investigator: Robert C. Bast, Jr., MD
Duration: 9/13/2000 - 8/31/2015

Last updated: 5/13/2013